SCHEMBL4512178

SCHEMBL4512178

CCOC(=O)c1sc2nc(Cc3ccc(Cl)c(Cl)c3)nc(Cl)c2c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.58
ALDH1A1 P00352 7/20 0.58
KMT2A Q03164 5/20 0.52
NPSR1 Q6W5P4 4/20 0.52
LMNA P02545 3/20 0.52
RXFP1 Q9HBX9 2/20 0.52
KCNH2 Q12809 1/20 0.52
SMN1; SMN2 Q16637 7/20 0.51
HPGD P15428 4/20 0.51
STAT3 P40763 1/20 0.51
MEN1 O00255 3/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 6/20 0.45
GAA P10253 2/20 0.45
HSD17B10 Q99714 2/20 0.45
PPARG P37231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4524904 0.91 KDM4E (0.55) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4510264 0.86 ALDH1A1 (0.57) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4531480 0.86 ALDH1A1 (0.61) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4514789 0.85 ALDH1A1 (0.55) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4531402 0.83 KDM4E (0.58) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4520550 0.83 ALDH1A1 (0.53) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4514505 0.81 KMT2A (0.65) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4513057 0.81 SMN1; SMN2 (0.44) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4515693 0.81 KMT2A (0.80) KDM4EALDH1A1KMT2ANPSR1LMNA
SCHEMBL4519168 0.80 KMT2A (0.48) KDM4EALDH1A1KMT2ANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 KDM4E 2859/4885ALDH1A1 2303/4885KMT2A 2650/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 KDM4E 2859/4885ALDH1A1 2303/4885KMT2A 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.